Literature DB >> 34127524

Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.

Huiyul Park1, Eileen L Yoon2, Dae Won Jun3, Eun-Hee Nah4, Seon Cho5.   

Abstract

Entities:  

Keywords:  nonalcoholic steatohepatitis

Mesh：

Year:  2021        PMID： 34127524     DOI： 10.1136/gutjnl-2021-325102

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

Review 1.  Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.

Authors:  Yi-Wen Shi; Jian-Gao Fan
Journal:  Acta Pharmacol Sin       Date:  2021-12-14       Impact factor: 7.169

2.  Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.

Authors:  Eun-Hee Nah; Seon Cho; Hyeran Park; Dongwon Noh; Eunjoo Kwon; Han-Ik Cho
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

Review 3.  A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Paul P Manka; Eda Kaya; Ali Canbay; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2021-08-19       Impact factor: 3.199

Review 4.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

5.  Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature.

Authors:  Eileen L Yoon; Dae Won Jun
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.